Drilldown: Medicines

Pharmacopedia is being built in public. Pages may be incomplete.About this site

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Benzodiazepine

or Botanical

or [[:Category:Antiarrhythmics|Antiarrhythmic (class IV)]]

Use the filters below to narrow your results.

None (32) · Calan, Calan SR, Verelan, Verelan PM, Isoptin SR (1) · Cardizem, Tiazac, Cartia XT, Dilacor XR, Taztia XT, Matzim LA (1) · Dalmane (1) · Doral (1) · Halcion (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Tranxene (1) · Versed (1) · Xanax (1)

None (1) · Apomorphine and nuciferine; dopaminergic activity (1) · Contains atropine, scopolamine, hyoscyamine (1) · Contains bufotenin and DMT (1) · Contains harmine, harmaline, tetrahydroharmine (1) · Contains ibogaine; kappa-opioid agonist (1) · Contains LSA (2) · Contains mescaline (2) · Contains muscimol and ibotenic acid (1) · Contains psilocybin and psilocin (1) · Contains salvinorin A (1) · DMT + MAOI (harmine/harmaline); 5-HT2A agonist (1) · DMT-containing plant used in psychedelic preparations (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · Kavalactones; GABAA modulator; sigma receptor activity (1) · Mechanism incompletely understood (1) · Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) · Partial MAOI; anticholinergic effects (1) · Partial mu-opioid receptor agonist; alpha-2 agonist (1) · Potent mu-opioid receptor agonist (1) · Reversible MAO-A inhibitor; beta-carboline (1) · Reversible MAO-A inhibitor; NMDA antagonist; beta-carboline (1) · Weak serotonin reuptake inhibitor; beta-carboline (1) · '"`UNIQ--vote-0000063C-QINU`"' Avoid in HFrEF (negative inotropy). CYP3A4 substrate AND moderate inhibitor — interacts substantially with statins (especially simvastatin), tacrolimus, cyclosporine, and many other CYP3A4 substrates'"`UNIQ--ref-0000063D-QINU`"'. (1)

None (45) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) · '"`UNIQ--vote-0000063E-QINU`"', '"`UNIQ--vote-0000063F-QINU`"', '"`UNIQ--vote-00000640-QINU`"', '"`UNIQ--vote-00000641-QINU`"' (1) · '"`UNIQ--vote-00000A66-QINU`"', '"`UNIQ--vote-00000A67-QINU`"', '"`UNIQ--vote-00000A68-QINU`"', '"`UNIQ--vote-00000A69-QINU`"', '"`UNIQ--vote-00000A6A-QINU`"' (1)

None (45) · 0.25 mg (1) · ER 180-240 mg PO once daily; IR 30 mg PO QID; IV 0.25 mg/kg over 2 min for acute rate control, then 5-15 mg/h infusion (1) · IR 80-120 mg PO TID; ER 180-240 mg PO daily; IV 2.5-5 mg over 2 min for SVT termination (under monitoring); cluster prophylaxis up to 480-960 mg/d in divided doses (1)

None (45) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · IR 30, 60, 90, 120 mg tablets; multiple ER capsules and tablets 60-420 mg; IV 5 mg/mL (1) · IR 40, 80, 120 mg tablets; SR/ER 100-360 mg; IV 2.5 mg/mL (1)

None (45) · 10 mg/d (1) · ~480 mg/d (oral) for cardiovascular indications; higher off-label for cluster (1) · ~480 mg/d (oral); IV per protocol (1)

None (45) · IV (2) · multiple ER formulations) (1) · Oral (1) · Oral (IR (1) · Oral (IR and multiple ER) (1)

None (45) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · IV: 1-3 minutes (SVT termination); PO IR: 30-60 minutes; ER: hours (1) · IV: 3-7 minutes (rate control); PO IR: 30-60 minutes; ER: hours (1)

None (45) · 6 h (immediate-release); ~11 h (extended-release) (1) · IR: 4-8 hours; ER: 24 hours (1) · IR: 6-8 hours; ER: 24 hours (1)

None (45) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · 3-4.5 hours (IR); 5-7 hours (ER; effective duration 24 hours via formulation)'"`UNIQ--ref-00000642-QINU`"' (1) · 3-7 hours (IR); functional 24 hours (ER)'"`UNIQ--ref-00000A6B-QINU`"' (1)

None (45) · 80-90% oral (1) · ~20-35% (oral; extensive first-pass via CYP3A4 with R/S enantiomer differences)'"`UNIQ--ref-00000A6C-QINU`"' (1) · ~40% (oral; extensive first-pass via CYP3A4)'"`UNIQ--ref-00000643-QINU`"' (1)

None (45) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Limited data; alternative antihypertensives generally preferred. Crosses placenta.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Limited data; labetalol/nifedipine generally preferred. Crosses placenta.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (45) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US (2)